DoD Peer Reviewed Medical, Technology/Therapeutic Development Award

Background
The PRMRP Technology/Therapeutic Development Award (TTDA) is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life, for a disease or condition related to one of the FY24 PRMRP Topic Areas and one of the FY24 PRMRP Strategic Goals.
The vision of the PRMRP is to improve the health, care, and well-being of all military Service Members, Veterans, and their Families.

Grant Details
The U.S. Army Medical Research Acquisition Activity (USAMRAA) is soliciting applications to the fiscal year 2024 (FY24) Peer Reviewed Medical Research Program (PRMRP) using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001).
The Technology/Therapeutic Development Award is not intended for basic research.
The award mechanisms are aligned to different phases of the research development pipeline including Basic Research phase, Translational Research phase, and Clinical Trials/Clinical Research phase.
The Technology/Therapeutic Development Award will only support research in the final stages of preclinical development.
The anticipated direct costs budgeted for the entire period of performance for an FY24 PRMRP Technology/Therapeutic Development Award should not exceed $4.0M.

Eligibility Requirements
Extramural and Intramural organizations are eligible to apply.

Period of Performance
The period of performance for awards made under this program announcement will be no later than September 30, 2025.
Funds to be obligated on any award resulting from this funding opportunity will be available for use until September 30, 2030.

Grant Value
$90.0M is expected to be allotted to fund approximately 15 FY24 PRMRP Technology/Therapeutic Development Award applications with an anticipated direct cost budget not exceeding $4.0M.